natgillin/translations-raw huggingface dataset:
The method as claimed in claim 9, wherein sensing the position and voice identity of each individual speaker (16) comprises employing a plurality of sound sensors and at least one sound location sensor (22), and wherein at least one of the sound sensors being a microphone (20). 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se detektiranje položaja 1 identiteta glasa svakog pojedinačnog govornika (16) sastoji u upotrebi više senzora zvuka i najmanje jednog senzora položaja zvuka (22), te što što je najmanje jedan od senzora zvuka mikrofon (20).
ii) transferring said raw liquid waste from said collecting tank to a non-stirred, flow-through channel reactor, said raw liquid waste providing a pretreated liquid waste in said channel; 
ii) prenošenje navedenog sirovog otpada iz navedenog sabirnog spremnika u reaktor protočnog kanala koji ne miješa (2), navedeni sirovi tekući otpad pruža prethodno obrađeni tekući otpad u navedeni kanal;
at the 5' end of the modified oligonucleotide; or ii) at the 3' end of the modified oligonucleotide. 
na 5’ kraju modificiranog oligonukleotida; ili ii) na 3’ kraju modificiranog oligonukleotida.
The method of claim 1, wherein the program receiver selects from ones of the possible media items that match profile data associated with the program receiver. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što prijemnik (1) snima u lokalni spremnik moguće medijske točke koje odgovaraju podacima o profilu povezanim s prijemnikom (1).
PEGylated GLP-1 compounds of the present invention comprise an amino acid sequence of the formula: 
PATENTNI ZAHTJEVI L m ll. Di-PEGilirani GLP-1 spoj s aminokiselinskim slijedom formule:
Background of the Invention Individual section glassware forming machines typically include an invert arm assembly which is oscillated or rotated approximately 180 degrees to transfer a glass blank from a blank mold to a final (blow) mold in which the glassware is formed into its desired final shape. 
Pojedinačni dijelovi stroja za oblikovanje stakla tipično sadrže sklop invertirajuće (okretajuće) ruke koji oscilira ili rotira približno za 180 stupnjeva kako bi prenio staklenu sirovinu iz prvog kalupa u završni (puhački) kalup u kojem se staklo oblikuje u svoj konačni željeni oblik.
The compound of Claim 1 wherein R1 is methylaminomethyl, R2 is hydrogen, R3 is fluoro, and R4 is fluoro or a pharmaceutically acceptable salt thereof 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je metilaminometil, R2 je vodik, R3 je fluor, a R4 je fluor, ili njegova farmaceutski prihvatljiva sol.
The reaction mixture was heated to reflux for 2 hr and chilled to 0-5° C. The solid was filtered and purified with isopropyl alcohol (27 ml) to give 8.52 g of the title compound. 
Reakcijska mješavina je zagrijavana do refluksa tijekom 2 sata i ohlađena na 0-5 *C. Kruta tvar je isfiltrirana i pročišćena s izopropil alkoholom (27 ml) da bi se dobilo 8,52 g spoja iz naslova.
A precipitate formed immediately. 
Precipitat se formira odmah.
Ribbed foundation for superstructures according to claim 1 or 2, where the reinforced-concrete ribs (2) have a constant or variable edge, either a stepped edge (5) or an edge having a constant slope, said slope decreasing as it moves away from the center of the slab (1). 
Rebrasti temelj za superstrukture u skladu s patentnim zahtjevom 1 ili 2, gdje rebra od prenapregnutog betona (2) imaju stalni ili varijabilni rub, bilo stepenasti rub (5) ili rub koji ima stalni nagib, navedeni nagib se smanjuje s udaljavanjem od središta podloge (1).
A pharmaceutical tablet especially in accordance with the preceding items having a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test. 
Farmaceutska tableta prema bilo kojem od prethodnih zahtjeva naznačena time da ima dubinu prodiranja s razmakom pukotine od najmanje 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm, te najpoželjnije 1.6 mm, kada je podvrgnuta indentacijskom testu.
Such an approach could be very sensible; in fact, the mechanics and the electronics have little in common; in general there is no advantage in placing them close to one another (on the contrary, it may be difficult), and it is quite often necessary to keep them distant from each other. 
Takav pristup može biti vrlo osjetljiv; u stvari, mehanički elementi i elektronički elementi imaju vrlo malo zajedničkog; općenito ne postoji prednost u tome da se oni stave jedni uz druge (baš suprotno, to može biti otežavajuće), i vrlo često je potrebno da se oni drže na udaljenosti jedni od drugih.
the organic or inorganic base is selected from the group consisting of trometamol, trimethylamine, dimethylamine, ethylamine, trimethylamine, diethylamine, L-lysine, L-arginine, diethanolamine, sodium hydroxide, 
organska ili anorganska baza odabrana iz skupine koju čine trometamol, trimetilamin, dimetilamin, etilamin, trimetilamin, dietilamin, L-lizin, L-arginin, dietanolamin, natrijev hidroksid,
Preferred are modified and unmodified synthetic polycarboxylate polymers, which typically have a weight average molecular weight of at least about 10,000 Daltons, preferably at least about 50,000 Daltons, more preferably at least about 100,000 Daltons, still more preferably at least about 1,000,000 Daltons, and most preferably from about 1,000,000 to about 10,000,000 Daltons. 
Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time,da bioljepljivi materijal ima težinsko sredstvo prosječne molekularne mase od najmanje 10 000 Daltona, poželjno najmanje 50 000 Daltona, poželjnije najmanje 100 000 Daltona, još više poželjno najmanje 1 000 000 Daltona, te najpoželjnije od 1 000 000 do 10 000 000 Daltona.
the chemical modification comprises the inclusion of a poly A tail to the 3' untranslated region of the mRNA; 
(v) kemijska modifikacija podrazumijeva uključivanje poli A repa na 3' netranslatirajuću regiju iRNK;
An isolated monoclonal anti-DLL3 antibody comprising a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213, wherein the antibody is conjugated to a cytotoxic agent. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:212 1 varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:213.
Process according to any of the previous claims, wherein a second membrane is used to separate sulphuric acid from a stream rich in monosaccharides, which is obtained after hydrolysis of said organic matter using sulphuric acid, thus producing a weak sulphuric acid stream, after which said stream rich in monosaccharides is fed to a fermentor and said weak sulphuric acid stream is fed to an anaerobic acidification and sulphate reduction step. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time, da se koristi druga membrana za odvajanje sumporne kiseline od toka bogatog monosaharidima, koji se dobije nakon hidrolize spomenutih organskih tvari uporabom sumporne kiseline, te time proizvodnjom toka slabe sumporne kiseline, nakon čega se spomenuti tok bogat monosaharidima ubacuje u fermentor, a spomenuti tok slabe sumporne kiseline se ubacuje u fazu anaerobne acidifikacije i sulfatne redukcije. t>&
The rotary machine according to claim 9, wherein the machine comprises several pairs of mechanisms (1), wherein the pendulum (4) of each of the respective supports of the several pairs of mechanisms being placed in series and synchronised within each pair, the several pairs being placed in parallel and synchronized among themselves. 
Rotacijski stroj prema zahtjevu 9 naznačen time da se stroj sastoji od više parova mehanizama (1) s polugom (4), pri čemu su mehanizmi (1) poredani u seriju i sinkronizirani unutar svakog para, a parovi poredani paralelno i međusobno sinkronizirani.
In a preferred embodiment the pharmaceutical composition as disclosed the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), imiquimod, resiquimod, and interferon-alpha. 
Farmaceutski sastav prema zahtjevu 5, gdje je adjuvans odabran iz skupine koja sadrži čimbenike za poticanje kolonija kao što su čimbenik za poticanje granulocitnih i makrofagnih kolonija (GM-CSF), odnosno imikvimod ili resikvimod.
The formulation of claim 1 wherein the amino acid is selected from the group consisting of glycine, histidine, proline, serine, alanine and arginine. 
Formulacija prema zahtjevu 1, naznačena time da je amino kiselina izabrana iz grupe koju čine glicin, histidin, prolin, serin, alanin 1 arginin.
Using the mother liquors from the first recrystallization, the solvent was eliminated at reduced pressure and the resulting residue recrystallized from dioxane to obtain 1 g of the product of interest (4bis) with a purity of 95% by HPLC. 
Upotrebom matičnice od prve prekristalizacije, otapalo se odstrani pod smanjenim tlakom i dobiveni ostatak se prekristalizira iz dioksana, čime se dobije 1 g željenog proizvoda (4bis) čistoće 95% pomoću HPLC.
and pharmaceutically acceptable salts and prodrugs thereof, wherein 
iH ili njena farmaceutski prihvatljiva sol, pri čemu:
Another problem which should be held in mind is the fact that to a fixed size there corresponds a fixed shape of the calf of the user, for which the use of larger sizes and the compensation of the greater space for the foot with a sock may bring about localized areas of compression of the upper end of the cuff on the calf. 
Drugi problem koji bi trebalo imati na umu je činjanica da fiksna veličina odgovara fiksnom obliku lista noge korisnika, kojem upotreba većih veličina i kompenzacija većeg prostora za stopalo sa čarapom može uzrokovati mjestimična područja pritiska gornjeg kraja manžete na list.
The pharmaceutical composition as defined in claim 3 for use according to claim 7, wherein the Clostridium difficile strain is a Nap1 Clostridium difficile strain. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je soj bakterije Clostridium difficile soj Napl bakterije Clostridium difficile.
In one aspect, the teaching relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5 or a variant of said amino acid sequence. In one embodiment the peptide is 100 or less, 50 or less, 20 or less, or 10 or less amino acids long. 
HR P20190472 T1 PATENTNI ZAHTJEVI Peptid koji sadrži aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEK ID BR: 3, 4 1 5, naznačen time, da je navedeni peptid dužine 100 aminokiselina ili manje, 50 aminokiselina ili manje, 20 aminokiselina ili manje, ili 10 aminokiselina ili manje.
a serum half life which is elongated by factor 2 compared to an antibody which carries no or a low degree of detectable sialylation; 
(b) poluvijek u serumu koji je 2 puta dulji u usporedbi s protutijelom koje nije sijalilirano ili ima nizak stupanj opazivog sijaliliranje;
An antibody directed against the extracellular part of Sortilin and capable of inhibiting binding of a pro-neurotrophin to a binding site on the Sortilin receptor, wherein the antibody is directed against a sequence having SEQ ID NO: 25, SEQ ID NO. 
Protutijelo usmjereno prema izvanstaničnom dijelu Sortilina koje je sposobno inhibirati vezanje pro-neurotrofina za vezno mjesto receptora Sortilina, pri čemu se protutijelo veže za motiv vezanja za pro-neurotrofin u skladu sa SEQ ID NO:25, 26, 27 ili 28 ili za njegov fragment.
The reaction condition was as described in Engelman, A. and Craigie, R. J. Virol. 
Reakcijski uvjeti su bili kao što je opisano u A. Engelman and R. Craigie, J. Virol.
The method according to claim 1, wherein the material is electronic waste, preferably used electronic circuit boards. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je taj elektronički otpad korištene elektroničke ploče.
The method of para 61, wherein the FcRH5-positive cancer is a B-cell proliferative disorder. The method of any one of paras 61-62, further comprising administering an additional therapeutic agent to the individual. A method of inhibiting proliferation of an FcRH5-positive cell, the method comprising exposing the cell to the antibody of any one of paras 1-36 and/or immunoconjugate of any one of claims 41-59 under conditions permissive for binding of the antibody and/or immunoconjugate to FcRH5 on the surface of the cell, thereby inhibiting proliferation of the cell. 
Protutijelo anti-FcRH5 prema bilo kojem od zahtjeva 1 do 6 i/ili imunokonjugat prema zahtjevu 10 ili 11, naznačen/o time, da se upotrebljava u postupku inhibiranja proliferacije stanice koja je pozitivna na FcRH5, pri čemu taj postupak obuhvaća izlaganje stanice koja je pozitivna na FcRHS, protutijelu anti-FcRH5 i/ili imunokonjugatu, pod uvjetima koji su tolerantni za vezanje protutijela anti-FcRHS5S i/ili imunokonjugata na FcRH5, na površini stanice koja je pozitivna na FcRH5, čime se inhibira proliferacija stanice pozitivne na FCRH5, dok se opcijski kod stanice koja je pozitivna na FcRH5, radi o B-stanici.
The electronic identification document (100) according to claim 2 or 3, wherein said communication means (102) are configured for powering said processing means (103) and/or said sensor means (101). 
Elektronički identifikacijski dokument (100) u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da su navedena komunikacijska sredstva (102) konfigurirana za napajanje navedenih procesnih sredstava (103) i / ili navedenih senzorskih sredstava (101).
At the typical substrate temperature (240°C) 23% of the neat RME had evaporated. 
Na tipičnoj temperaturi podloge (240%C) isparilo je 23% čistog RME-a.
As shown in Table 5, 42-O-(D-Fractosylcarbonyl)rapamycin prolonged survival of the graft at the 2.5 and 10 mg/kg/day dose level by 214 and 341% over the vehicle control. 
Kako je vidljivo iz Tablice 5, 42-0-(D- fruktozilkarbonil)rapamicin produljio je preživljenje transplantata u dozama od 2,5 mg/kg/dan i 10 mg/kg/dan i214i 341% više u usporedbi s kontrolom (nosačem).
• Mannich base hardeners which are obtained by reaction of mono- or polyhydric phenols with aldehydes, especially formaldehyde, and polyamines; 
• učvršćivači Mannichove baze koji se dobivaju reakcijom mono- ili polihidrioksilnih fenola s aldehidima, naročito formaldehidom, te poliaminima;
A method according to claim 1, wherein the amount in weight of applied adhesive in the adhesion method based on atmospheric plasma treatment is significantly less than in the adhesion method without atmospheric plasma treatment, wherein the bonding strength of atmospheric plasma-treated bonded materials and non atmospheric plasma-treated bonded materials are essentially the same. 
Metoda u skladu sa patentnim zahtjevom 1, gdje je masa primijenjenog adheziva u metodi adhezije zasnovanoj na tretmanu atmosferskom plazmom značajno manja nego u metodi adhezije bez tretmana atmosferskom plazmom, gdje jačina vezivanja vezanih materijala tretiranih atmosferskom plazmom i vezanih materijala tretiranih neatmosferskom plazmom su suštinski iste.
1, the cooling system 6 (generally composed of an evaporator 6 A, a compressor and a condenser, these two not shown) is shown very diagrammatically; the evaporator 6 A inside the refrigerated space 21 may be noted. 
Na slici 1 je sustav za hlađenje 6 (koji se općenito sastoji od isparivača 6A, kompresora i kondenzatora, koji nisu prikazani) prikazan vrlo shematski; može se primijetiti da se isparivač 6A nalazi unutar prostora 21 koji se hladi.
The present invention relates to a single-chain fusion polypeptide comprising: 
HR P20150425 T1 PATENTNI ZAHTJEVI Jednolančani fuzijski polipeptidni lanac sadrži:
Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the relevant fields are intended to be within the scope of the present invention. The use of a composition comprising Sel-Plex in the manufacture of a medicament for a treatment for Alzheimer's disease, wherein the medicament is formulated for administration to a subject under conditions such that the expression of a complement gene is reduced in the cerebral cortex of said subject. 
HR P20120337 T1 PATENTNI ZAHTJEVI Pripravak koji se koristi u proizvodnji lijeka sadrži suhi, neživi kvasac obogaćen selenom, naznačen time da u ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, pri čemu je lijek formuliran za primjenu u subjektu pod uvjetom da se izražavanje komplement gena smanjuje u moždanoj kori tog subjekta u svrhu liječenja ili prevencije Alzheimerove bolesti.
The duct member (1, 10) according to claim 5, characterized in that the locking element is velcro. 
Element kanala (1, 10) prema zahtjevu 5, naznačen time da je blokirajući element velcro traka.
Certain compounds of the present invention may exist in different stable conformational forms, which may be separable. 
Izvjesni spojevi prema ovom izumu mogu postojati u različitim stabilnim konformacijskim oblicima (konformerima), koje se može razdvojiti.
said antibody is a monoclonal antibody capable of specific binding to Lymphocyte antigen 75 and which has cytotoxicity against Lymphocyte antigen 75 expressing cells in the presence of human immune effector cells. 
(E) spomenuto antitijelo je monoklonalno antitijelo sposobno za specifično vezivanje na limfocitni antigen 75 1 koji ima citotoksičnost protiv stanica koje izražavaju limfocitni antigen 75 uz prisutnost ljudskih efektornih imunosnih stanica.
a heavy chain variable region comprising SEQ ID NO: 5 or a variant thereof, wherein said variant comprises one, two or three conservatively modified amino acids; and 
aminokiselinski ostaci 20 do 139 iz sekv. id. br.: 30 ili njene varijante, pri čemu navedena varijanta sadrži jednu, dvije ili tri konzervativno modificirane aminokiselinske supstitucije; i
The resulting fusion protein has improved properties, such as an extended residence time in body fluids (half-life), increased specific activity, increased expression level, or the purification of the fusion protein is facilitated. 
Nastali fuzijski protein posjeduje poboljšane karakteristike poput produžene otpornosti u tjelesnim tekućinama (polu život), povećanu specifičnu aktivnost, povećanu razinu ekspresije ili je pročišćavanje fuzijskog proteina ubrzano.
The main object of the present invention is to provide a novel agent for the treatment of inflammatory bowel diseases. 
(54) Naziv izuma: SREDSTVO ZA TERAPIJU UPALNE BOLESTI CRIJEVA HR P20170030 T1
The selective 5HT-2C receptor agonist for use or the composition according to any one of claims 1 to 4 wherein said selective 5HT-2C receptor agonist is selected from the group consisting of: 
Pripravak u skladu sa zahtjevom 1, naznačen time, da je navedeni selektivni agonist 5HT-2C receptora izabran iz skupine koju čine slijedeći spojevi i njihove farmaceutski prihvatljive soli, solvati i hidrati:
A variant according to any one of claims 1-6 for use in a method of treating an immune disorder in a human patient, wherein the method comprises administering to the patient a therapeutically effective amount of the variant. 
Varijanta u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time, da je to varijanta za uporabu u postupku liječenja imunoloških poremećaja kod ljudskih pacijenata, pri čemu postupak podrazumijeva davanje terapijski djelotvorne količine varijante pacijentu.
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent, to obtain a compound of formula IIa in the form of diastereoisomeric mixture (S,R+R,R) 
pomoću reakcije C-C vezivanja katalizirane paladijem, da bi se dobio spoj formule Xla u obliku dijasteroizomerne smjese (S, R+R, R) "A Kla(SREKE) u
In this embodiment, preferably, the closure 22 is comprised by a separate seal sealingly arranged on and to an upper rim 41 of the preferably annular cup-shaped part 40. 
U ovoj izvedbi, ponajprije, poklopac 22 je stisnut s odvojenom brtvom, koja je postavljena tijesno na njega i prema gornjem rubu 41 ponajprije kružnog dijela 40 oblika čašice.
EXAMPLES Example 1 Manufacture of Lozenges (General Procedures and Equipment) 
PRIMJERI Primjer 1 - Proizvodnja tableta-pastila (Opći postupci i oprema)
Cortexolone-17a-propionate in hydrate crystalline form IV according to any one of claims 21 to 22 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku INI u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili derivate kože.
Isomer C, which is believed to have either the 2 R,3 S,11b R or 2 S,3 R,11b S configuration (the absolute stereochemistry was not determined), was characterized by 1H-NMR, 13C-NMR, IR, mass spectrometry, chiral HPLC and ORD. 
Izomer €, za kojeg se smatra da ima ili 2R,38,11bR ili 25,3R,11bS konfiguraciju (apsolutna stereokemija nije određena) je okarakteriziran pomoću 'H-NMR, '*C-NMR, IR, masene spektrometrije, hiralne HPLC i ORD.
The peptide of claim 2, wherein the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO:376 or 379 is substituted with leucine or methionine. 
Peptid u skladu s patentnim zahtjevom 2, naznačen time što je druga aminokiselina od N-kraja u aminokiselinskom slijedu SEQ ID NO: 194, 174, 178 ili 186 zamijenjena fenilalaninom, tirozinom, metioninom ili triptofanom.
Cool down gently by placing the bowl containing the pastry cream in an ice bath. 
Polako ohladiti stavljanjem posude s kremom u ledenu kupelj.
The method of claim 25, wherein therapeutically effective amount of Crenolanib or a salt thereof is administered up to three times or more a day for as long as the subject is in need of treatment for the proliferative disease. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove soli daje tri ili više puta dnevno sve dok je subjektu potrebno liječenje akutne mijeloične leukemije (AML).
A transdermal delivery device comprising: a drug containing layer comprising an effective amount of an opioid agonist and a plurality of microspheres dispersed in the drug containing layer, the microspheres comprising an opioid antagonist and in a mean size of from about 1 to about 500 µm in diameter. 
Sredstvo za transdermalno davanje koje sadrži: sloj koji sadrži lijek gdje navedeni sloj sadrži učinkovitu količinu opioidnog agonista i veći broj mikrosfera dispergiranih u sloju koji sadrži lijek, mikrosfere koje sadrže opioidni antagonist i gdje su mikrosfere srednje veličine od 1 do 300 um u promjeru.
An antibody or antigen-binding fragment thereof that specifically binds human interleukin-4 receptor (hIL-4R) (SEQ ID NO:274) for use in a method of treating a disease or disorder, wherein the disease or disorder is selected from the group consisting of lung disorders, inflammatory disorders and allergic reactions, wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence shown in SEQ ID NO:162 and a light chain variable region (LCVR) comprising the amino acid sequence shown in SEQ ID NO:164. 
Antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično vezuje za humani interleukin-4 receptor (hIL-4R) (SEQ ID NO:274) za primjenu u metodi liječenja oboljenja ili poremećaja, naznačena time, što je oboljenje 1li poremećaj odabran iz skupine koja se sastoji od oboljenja pluća, upalnih poremećaja 1 alergijskih reakcija, pri čemu antitijelo ili njegov fragment sadrži varijabilnu regiju teškog lanca (HCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NOQO:162 i varijabilnu regiju lakog lanca (LCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:164.